Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE
Matthew M. Seavey, Lily D. Lu, Kristine L. Stump, Nate H. Wallace, Bruce A. RuggeriVolume:
12
Year:
2012
Language:
english
DOI:
10.1016/j.intimp.2011.11.019
File:
PDF, 2.05 MB
english, 2012